Joseph S Koopmeiners

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/549086/joseph-s-koopmeiners-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 1,479 19 37 g-index

72 1,848 5.6 4.54 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
69	Calibrated dynamic borrowing using capping priors Journal of Biopharmaceutical Statistics, 2022, 1-16	1.3	
68	Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial <i>JAMA Network Open</i> , 2022 , 5, e222735	10.4	10
67	A permutation procedure to detect heterogeneous treatments effects in randomized clinical trials while controlling the type I error rate <i>Clinical Trials</i> , 2022 , 17407745221095855	2.2	1
66	Dynamic borrowing in the presence of treatment effect heterogeneity. <i>Biostatistics</i> , 2021 , 22, 789-804	3.7	2
65	Bayesian spatial models for voxel-wise prostate cancer classification using multi-parametric magnetic resonance imaging data. <i>Statistics in Medicine</i> , 2021 ,	2.3	2
64	Responses to Gradual and Immediate Reduction of Nicotine in Cigarettes in Young Versus Older Adult Smokers. <i>Nicotine and Tobacco Research</i> , 2021 , 23, 1559-1566	4.9	2
63	A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. <i>Pharmaceutical Statistics</i> , 2021 , 20, 1249-1264	1	
62	Borrowing from supplemental sources to estimate causal effects from a primary data source. <i>Statistics in Medicine</i> , 2021 , 40, 5115-5130	2.3	1
61	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> , 2021 , 37, 100957	11.3	21
60	Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarker. <i>Clinical Trials</i> , 2021 , 18, 28-38	2.2	
59	Statistical design considerations for trials that study multiple indications. <i>Statistical Methods in Medical Research</i> , 2021 , 30, 785-798	2.3	3
58	Support for a nicotine reduction policy among participants enrolled in a 20-week trial of very low nicotine content cigarettes. <i>Addictive Behaviors</i> , 2021 , 114, 106727	4.2	О
57	Impact of nicotine reduction in cigarettes on smoking behavior and exposure: Are there differences by race/ethnicity, educational attainment, or gender?. <i>Drug and Alcohol Dependence</i> , 2021 , 225, 108756	4.9	1
56	Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1673-1678	4	4
55	A fully Bayesian mixture model approach for identifying noncompliance in a regulatory tobacco clinical trial. <i>Statistics in Medicine</i> , 2020 , 39, 1328-1342	2.3	
54	The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 880-886	4	9
53	Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 643-649	4	3

(2018-2019)

52	Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine. <i>American Journal of Preventive Medicine</i> , 2019 , 57, 515-524	6.1	15
51	Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. <i>Addiction</i> , 2019 , 114, 1824-1833	4.6	3
50	Signature maps for automatic identification of prostate cancer from colorimetric analysis of H&E-and IHC-stained histopathological specimens. <i>Scientific Reports</i> , 2019 , 9, 6992	4.9	3
49	Classification Accuracy of Biomarkers of Compliance. <i>Tobacco Regulatory Science (discontinued)</i> , 2019 , 5, 301-319	2	2
48	Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S63-S72	4.9	11
47	The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S73-S80	4.9	11
46	The Importance of Estimating Causal Effects for Evaluating a Nicotine Standard for Cigarettes. <i>Nicotine and Tobacco Research</i> , 2019 , 21, S22-S25	4.9	3
45	Basket Designs: Statistical Considerations for Oncology Trials <i>JCO Precision Oncology</i> , 2019 , 3, 1-9	3.6	2
44	Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. <i>Tobacco Control</i> , 2019 , 28, 352-355	5.3	4
43	Age Moderates Smokers L Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2019 , 21, 962-969	4.9	19
42	Bayesian hierarchical modeling based on multisource exchangeability. <i>Biostatistics</i> , 2018 , 19, 169-184	3.7	25
41	A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. <i>Biometrics</i> , 2018 , 74, 1082-1094	1.8	20
40	Development of a measure for evaluating lesion-wise performance of CAD algorithms in the context of mpMRI detection of prostate cancer. <i>Medical Physics</i> , 2018 , 45, 2076-2088	4.4	4
39	Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 1547-1558	2.3	7
38	Hierarchical models for sharing information across populations in phase I dose-escalation studies. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 3447-3459	2.3	4
37	Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks. <i>Tobacco Control</i> , 2018 , 27, 420-426	5.3	17
36	Efficacy/toxicity dose-finding using hierarchical modeling for multiple populations. <i>Contemporary Clinical Trials</i> , 2018 , 71, 162-172	2.3	1
35	Efficiency and robustness of causal effect estimators when noncompliance is measured with error. <i>Statistics in Medicine</i> , 2018 , 37, 4126-4141	2.3	3

34	Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. <i>Statistics in Medicine</i> , 2018 , 37, 3214-3229	2.3	7
33	Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. <i>Biostatistics</i> , 2018 , 19, 103-118	3.7	9
32	Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 880-891	27.4	76
31	Identifying optimal approaches to early termination in two-stage biomarker validation studies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 187-199	1.5	2
30	The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM. <i>Journal of Biopharmaceutical Statistics</i> , 2017 , 27, 1028-1042	1.3	1
29	Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1093-1099	4	16
28	Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017 , 26, e43-e48	5.3	13
27	A multiplex platform for the identification of ovarian cancer biomarkers. <i>Clinical Proteomics</i> , 2017 , 14, 34	5	16
26	A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines. <i>Statistics in Medicine</i> , 2017 , 36, 43-53	2.3	19
25	Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017 , 19, 59-67	4.9	40
24	Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence. <i>Statistics in Medicine</i> , 2016 , 35, 1267-80	2.3	3
23	Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016 , 14, 51	8.5	3
22	Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1906-13	7	34
21	Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology. <i>Radiology</i> , 2016 , 279, 805-16	20.5	41
20	mHealth Pilot Study: Text Messaging Intervention to Promote HPV Vaccination. <i>American Journal of Health Behavior</i> , 2016 , 40, 67-76	1.9	41
19	Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016 , 2, 186-203	2	23
18	Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016 , 111, 2208-2216	4.6	37
17	Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. <i>Drug and Alcohol Dependence</i> , 2016 , 167, 228-32	4.9	16

LIST OF PUBLICATIONS

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. <i>New England Journal of Medicine</i> , 2016 , 375, 1448-1456	59.2	339
Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 472-6	4	41
Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015 , 373, 1340-9	59.2	237
Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. <i>Chemical Research in Toxicology</i> , 2015 , 28, 2390-9	4	16
A double blinded, placebo-controlled pilot study to examine reduction of CD34/CD117/CD133 lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. <i>F1000Research</i> , 2015 , 4, 42	3.6	4
Evaluation of protein biomarkers of prostate cancer aggressiveness. <i>BMC Cancer</i> , 2014 , 14, 244	4.8	31
A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes. <i>Clinical Trials</i> , 2014 , 11, 38-48	2.2	10
Evaluating the performance of copula models in phase I-II clinical trials under model misspecification. <i>BMC Medical Research Methodology</i> , 2014 , 14, 51	4.7	19
Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention. <i>Journal of Medical Internet Research</i> , 2014 , 16, e196	7.6	70
Discussion of Umall-sample behavior of novel phase I cancer trial designs by Assaf P Oron and Peter D Hoff. <i>Clinical Trials</i> , 2013 , 10, 81-5; discussion 88-92	2.2	4
Early termination of a two-stage study to develop and validate a panel of biomarkers. <i>Statistics in Medicine</i> , 2013 , 32, 1027-37	2.3	9
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility. <i>Statistics in Medicine</i> , 2012 , 31, 420-35	2.3	23
A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy. <i>Statistics in Medicine</i> , 2012 , 31, 3885-95	2.3	25
Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling. <i>Annals of Statistics</i> , 2011 , 39, 3234-3261	3.2	9
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. <i>Statistics in Medicine</i> , 2009 , 28, 762-79	2.3	30
Multi-resolution super learner for voxel-wise classification of prostate cancer using multi-parametric MRI. <i>Journal of Applied Statistics</i> ,1-22	1	1
	Medicine, 2016, 375, 1448-1456 Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 472-6 Randomized Trial of Reduced-Nicotine Standards for Cigarettes. New England Journal of Medicine, 2015, 373, 1340-9 Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine in Urine: Effects of Cigarette Smoking. Chemical Research in Toxicology, 2015, 28, 2390-9 A double blinded, placebo-controlled pilot study to examine reduction of CD34/CD117/CD133 lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Research, 2015, 4, 42 Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer, 2014, 14, 244 A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes. Clinical Trials, 2014, 11, 38-48 Evaluating the performance of copula models in phase I-II clinical trials under model misspecification. BMC Medical Research Methodology, 2014, 14, 51 Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention. Journal of Medical Internet Research, 2014, 16, e196 Discussion of Bmall-sample behavior of novel phase I cancer trial designs by Assaf P Oron and Peter D Hoff. Clinical Trials, 2013, 10, 81-5; discussion 88-92 Early termination of a two-stage study to develop and validate a panel of biomarkers. Statistics in Medicine, 2012, 31, 388-95 A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy. Statistics in Medicine, 2012, 31, 3885-95 A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy. Statistics in Medicine, 2012, 31, 3885-95 A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy. Statistics in	Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 472-6 Randomized Trial of Reduced-Nicotine Standards for Cigarettes. New England Journal of Medicine, 2015, 373, 1340-9 Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarettes Smoking. Chemical Research in Toxicology, 2015, 28, 2390-9 A double blinded, placebo-controlled pilot study to examine reduction of CD34 /CD117 /CD133 lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma. F1000Research, 2015, 4, 42 Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer, 2014, 14, 244 A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes. Clinical Trials, 2014, 11, 38-48 Evaluating the performance of copula models in phase I-II clinical trials under model misspecification. BMC Medical Research Methodology, 2014, 14, 51 Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention. Journal of Medical Internet Research, 2014, 16, e196 Discussion of Bmall-sample behavior of novel phase I cancer trial designstby Assaf P Oron and Peter D Hoff. Clinical Trials, 2013, 10, 81-5; discussion 88-92 Early termination of a two-stage study to develop and validate a panel of biomarkers. Statistics in Medicine, 2012, 31, 420-35 A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy. Statistics in Medicine, 2012, 31, 3885-95 Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling. Annats of Statistics, 11, 39, 3234-3261 Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Statistics in Medicine, 2009, 28, 762-79